Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regenerex Pharma's book value per share for the quarter that ended in Sep. 2025 was $-0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
Regenerex Pharma's current price is $0.00. Its book value per share for the quarter that ended in Sep. 2025 was $-0.02. Hence, today's PB Ratio of Regenerex Pharma is .
Regenerex Pharma (OTCPK:RGPX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Regenerex Pharma Book Value per Share Related Terms
Regenerex Pharma Book Value per Share Historical Data
* Premium members only.
The historical data trend for Regenerex Pharma's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGPX vs CABN, TEKXD, DLYT: Book Value per Share Comparison
For the Medical Instruments & Supplies subindustry, Regenerex Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerex Pharma PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Regenerex Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Regenerex Pharma's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerex Pharma (RGPX) has a Book Value per Share of $-0.02 as of Sep. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Regenerex Pharma and its competitors.
Is Regenerex Pharma's Book Value per Share too high?
Regenerex Pharma's current Book Value per Share is $-0.02.
How does Regenerex Pharma's Book Value per Share compare to CABN and TEKXD?
Regenerex Pharma's Book Value per Share of $-0.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Devices & Instruments company?
A good Book Value per Share depends on the Medical Devices & Instruments industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Regenerex Pharma and its competitors. Regenerex Pharma's current Book Value per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerex Pharma stock overvalued right now?
Regenerex Pharma (RGPX) has a current Book Value per Share of $-0.02. The current Book Value per Share is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Regenerex Pharma (RGPX), the current Book Value per Share is $-0.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerex Pharma Inc develops and markets Woundcare Healing products. The current product technology provides the company with a number of complete wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns, and surgical wounds. Its product Xcellderma OTC a Liquid Bandage Skin Protectant Xcellderma products are sterile wound dressings for treating diabetic foot ulcers, pressure ulcers, and other chronic wounds; Accelerex Sterile Wound Cream is for the treatment of a wide variety of chronic and acute wounds; and Accelerex Impregnated Sterile Wound Dressing use as a wound dressing to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGPX has been successfully added to your 
